![Susanne Antonie Schaffert](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Susanne Antonie Schaffert
Directeur/Membre du Conseil chez
BIONTECH SE
Fortune : 602 222 $ au 31/07/2026
Profil
Susanne Antonie Schaffert is currently Director at Novo Holdings A, Independent Director at Vetter Pharma International GmbH and Artbio, Inc., Member-Supervisory Board at BioNTech SE starting 2026, Member-Supervisory Board at CIBA Vision GmbH (Germany), Member at E.
Merck KG, and Independent Member-Supervisory Board at Merck KGaA starting 2024.
Former roles include President & Chief Executive Officer at Novartis Oncology, Inc. from 2019 to 2022, Chairman & President at Advanced Accelerator Applications SA from 2018 to 2019, Director at Endocyte, Inc., Independent Director at Incyte Corp.
from 2022 to 2026, Independent Non-Executive Director at Lakefront Biotherapeutics from 2023 to 2025, Director at Rubius Therapeutics, Inc. from 2022 to 2023, and Global Head-Investor Relations at Novartis AG from 2011 to 2012.
Education includes graduate and doctorate degrees from Friedrich-Alexander University of Erlangen-Nuremberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/04/2026 | 4 871 ( 0% ) | 582 182 $ | 31/07/2026 | |
| 31/12/2025 | 730 ( 0% ) | 20 040 $ | 31/07/2026 |
Postes actifs de Susanne Antonie Schaffert
| Sociétés | Poste | Début |
|---|---|---|
| BIONTECH SE | Directeur/Membre du Conseil | 15/05/2026 |
| MERCK KGAA | Directeur/Membre du Conseil | 26/04/2024 |
CIBA Vision GmbH (Germany)
 CIBA Vision GmbH (Germany) Electronic ComponentsElectronic Technology Manufactures and markets contact lenses | Directeur/Membre du Conseil | - |
Novo Holdings A/S (Denmark)
 Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Directeur/Membre du Conseil | - |
Artbio, Inc.
 Artbio, Inc. Hospital/Nursing ManagementHealth Services Provides redefining cancer care services | Directeur/Membre du Conseil | - |
Vetter Pharma International GmbH
 Vetter Pharma International GmbH Medical DistributorsDistribution Services Wholesales pharmaceutical products | Directeur/Membre du Conseil | - |
E. Merck KG
 E. Merck KG Pharmaceuticals: MajorHealth Technology Operates as a holding company with interests in pharmaceutical preparations | Corporate Officer/Principal | - |
Anciens postes connus de Susanne Antonie Schaffert
| Sociétés | Poste | Fin |
|---|---|---|
| INCYTE CORPORATION | Directeur/Membre du Conseil | 15/04/2026 |
| LAKEFRONT BIOTHERAPEUTICS NV | Directeur/Membre du Conseil | 01/11/2025 |
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Susanne Antonie Schaffert
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Galapagos NV
 Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Novo Holdings A/S (Denmark)
Novo Holdings A/S (Denmark) Investment ManagersFinance Functions as an alternative investment manager | Finance |
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for cancer and inflammatory diseases | Health Technology |
Friedrich-Alexander University of Erlangen-Nuremberg
 Friedrich-Alexander University of Erlangen-Nuremberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
 BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
E. Merck KG
E. Merck KG Pharmaceuticals: MajorHealth Technology Operates as a holding company with interests in pharmaceutical preparations | Health Technology |
Advanced Accelerator Applications SA
 Advanced Accelerator Applications SA Pharmaceuticals: MajorHealth Technology Develops and produces nuclear medicine and radioligand therapies | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
Vetter Pharma International GmbH
Vetter Pharma International GmbH Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
CIBA Vision GmbH (Germany)
CIBA Vision GmbH (Germany) Electronic ComponentsElectronic Technology Manufactures and markets contact lenses | Electronic Technology |
Artbio, Inc.
Artbio, Inc. Hospital/Nursing ManagementHealth Services Provides redefining cancer care services | Health Services |
